Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

GNPX

Genprex Inc

Apr 16 • 04:00PM ET

2.30

Dollar change -0.05
Percentage change -2.13	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-22.93	Insider Own	3.22%	Shs Outstand	1.91M	Perf Week	-25.08%
Market Cap	4.39M	Forward P/E	-	EPS next Y	-12.39	Insider Trans	0.00%	Shs Float	1.85M	Perf Month	-43.07%
Income	-30.86M	PEG	-	EPS next Q	-4.07	Inst Own	6.60%	Short Float	3.78%	Perf Quarter	-73.38%
Sales	0.00M	P/S	-	EPS this Y	40.36%	Inst Trans	32.79%	Short Ratio	0.81	Perf Half Y	-82.31%
Book/sh	4.99	P/B	0.46	EPS next Y	10.77%	ROA	-172.62%	Short Interest	0.07M	Perf Year	-93.10%
Cash/sh	3.53	P/C	0.65	EPS next 5Y	-	ROE	-207.88%	52W Range	2.35 - 46.00	Perf YTD	-75.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.89%	ROI	-416.11%	52W High	-95.00%	Beta	-0.56
Dividend TTM	-	Quick Ratio	2.31	Sales past 5Y	0.00%	Gross Margin	-	52W Low	-2.13%	ATR (14)	0.36
Dividend Ex-Date	-	Current Ratio	2.31	EPS Y/Y TTM	-15.81%	Oper. Margin	0.00%	RSI (14)	27.33	Volatility	10.89% 11.04%
Employees	26	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	9.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	29.18%	Payout	-	Rel Volume	0.24	Prev Close	2.35
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	86.39K	Price	2.30
SMA20	-22.81%	SMA50	-41.72%	SMA200	-83.01%	Trades		Volume	20,368	Change	-2.13%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-26-21	Initiated	National Securities	Buy	$7
Apr-29-19	Initiated	Noble Capital Markets	Outperform	$5

Apr-09-24 08:31AM	Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting (PR Newswire)
Apr-04-24 08:57AM	Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up (Zacks)
Apr-03-24 08:31AM	Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer (PR Newswire) +9.51%
Apr-02-24 08:31AM	Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex Delivery System (PR Newswire)
Mar-22-24 04:10PM	Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
01:24PM	Loading…
Mar-19-24 01:24PM	Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) -17.36%
Mar-12-24 09:01AM	Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers (PR Newswire) -10.43%
Mar-06-24 08:30AM	Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting (PR Newswire) +6.31%
Feb-07-24 08:15AM	Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators (PR Newswire) -11.17%
Feb-06-24 07:30AM	Genprex to Present at Upcoming BIO CEO & Investor Conference (PR Newswire) -10.45%
Feb-05-24 07:30AM	Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer (PR Newswire) +13.37%
Jan-31-24 08:42AM	Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024 (PR Newswire) -29.13%
Jan-05-24 07:00AM	Genprex Provides Business Update and Outlook for 2024 (PR Newswire)
Nov-23-23 08:30AM	Genprex Granted Orphan Drug Designation in Small Cell Lung Cancer (NewMediaWire)
Nov-03-23 09:00AM	Genprex to Present at BIO-Europe 2023 (NewMediaWire) +27.29%
07:30AM	Loading…
Nov-01-23 07:30AM	Genprex to Present at BIO-Europe 2023 Conference (PR Newswire)
Oct-20-23 03:00PM	Genprex Schedules, Hosts Virtual Key Opinion Leader Event (NewMediaWire)
07:30AM	Genprex to Host a Virtual Key Opinion Leader Event on 'Bringing Gene Therapy to the Fight Against Lung Cancers' (PR Newswire)
Oct-06-23 09:00AM	Genprex to Unveil Encouraging Data on REQORSA(R) at AACR-NIH-EORTC Conference (NewMediaWire)
Oct-04-23 12:00PM	Genprex to Present Data on the Use of REQORSA for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire) +5.11%
Sep-21-23 08:30AM	Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC (GlobeNewswire)
Sep-19-23 09:00AM	Genprex Looks Forward to Acclaim-3 Trial on Heels of Receipt of FDA FTD and ODD Designations (NewMediaWire)
Sep-08-23 08:00PM	Genprex to Present at Upcoming H.C. Wainwright Conference (NewMediaWire) +6.72%
Sep-07-23 07:30AM	Genprex to Present at Upcoming September Investor Conference (PR Newswire)
Sep-04-23 12:00PM	GENPREX (GNPX) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-01-23 09:20PM	Genprex Secures Patent Protection in 'Some of the Most Important Markets in the World' (NewMediaWire)
Aug-31-23 12:44AM	Genprex Celebrates Receipt of Orphan Drug Designation, Third Fast Track Designation (NewMediaWire)
Aug-24-23 12:25AM	Genprex Appoints Regulatory Expert as It Drives Clinical Programs Forward (NewMediaWire)
Aug-23-23 02:06AM	5 big analyst cuts: BofA sees 'increased risks' for Dick's Sporting Goods (Investing.com) -5.20%
Aug-22-23 07:30AM	Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs (PR Newswire) +7.86%
10:24AM	Loading…
Aug-13-23 10:24AM	Genprex Granted FDA Orphan Drug Designation for REQORSA(R) for SCLC (NewMediaWire)
Aug-10-23 07:30AM	Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer (PR Newswire)
Aug-08-23 01:04AM	Genprex's Third Fast Track Designation Validates REQORSA(R)'s Potential (NewMediaWire)
Jul-28-23 08:00PM	Genprex Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in China (NewMediaWire) +5.92%
Jul-25-23 01:22AM	Genprex Inc. Closes on $7.5M Registered Direct Offering (NewMediaWire)
Jul-21-23 04:15PM	Genprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
12:57AM	Genprex Inc. Announces $7.5M Registered Direct Offering (NewMediaWire)
Jul-20-23 01:05AM	Genprex Enters Exclusive License Agreement with University of Pittsburgh (NewMediaWire)
Jul-19-23 08:00AM	Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire) -17.31%
12:37AM	Genprex Positioned to Expand Clinical Pipeline (NewMediaWire)
Jul-18-23 08:37AM	Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh (PR Newswire) +10.93%
Jul-12-23 01:00AM	Genprex Reports Positive Results From Phase 1 Acclaim-1 Clinical Trial (NewMediaWire) -8.95%
Jul-07-23 09:00PM	Genprex's Unique Treatment Paradigm Featured in Bell2Bell Podcast (NewMediaWire)
Jul-06-23 08:17AM	IBN Announces Latest Episode of The Bell2Bell Podcast featuring CEO Rodney Varner & CFO Ryan Confer of Genprex, Inc. (GlobeNewswire) -7.78%
12:51AM	Genprex Secures Chinese Patent, Exclusivity for REQORSA(R) Gene Therapy Combination (NewMediaWire)
Jul-05-23 08:35AM	Genprex Granted Chinese Patent for REQORSA® Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers (PR Newswire)
Jun-29-23 09:03PM	Genprex Receives Fast Track Designation for Immunogene Therapy (NewMediaWire)
Jun-28-23 08:35AM	Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer (PR Newswire) +6.50%
Jun-02-23 10:15AM	Genprex (NASDAQ:GNPX) Releases New Patient Video Interview Describing Positive Experience In Clinical Trial (ACCESSWIRE) +11.35%
Jun-01-23 11:59AM	Genprex (GNPX) Up on Advancing Early-Stage NSCLC Study (Zacks) +8.45%
May-31-23 12:59AM	Genprex Receives Approval to Advance to Phase 2 of REQORSA(R) Trial (NewMediaWire) +7.22%
May-30-23 07:30AM	Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer (PR Newswire) -9.75%
May-26-23 06:00PM	Genprex Announces Results of Phase 1 Trial Will Be Published at ASCO Meeting (NewMediaWire)
May-25-23 05:00PM	Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting (PR Newswire) +8.99%
May-23-23 07:30AM	Genprex Unveils New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System (PR Newswire)
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-08-23 07:30AM	Genprex to Participate and Present at Upcoming May Industry and Investor Conferences (PR Newswire)
May-02-23 03:30PM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
Apr-19-23 09:11AM	Genprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System in Non-Small Cell Lung Cancer at the 2023 AACR Annual Meeting (PR Newswire)
Apr-18-23 09:11AM	Independent Researchers Find That TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma (PR Newswire)
Apr-03-23 06:12AM	Is Genprex (NASDAQ:GNPX) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-23-23 07:30AM	Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies (PR Newswire)
Mar-13-23 07:30AM	Genprex to Present at Bioprocessing Summit Conference (PR Newswire)
Mar-08-23 07:30AM	Genprex to Participate in March Investor and Industry Conferences (PR Newswire)
Feb-27-23 08:30AM	Genprex, Inc. Announces $4 Million Registered Direct Offering With a Single, Healthcare-Focused Institutional Investor (PR Newswire) -14.71%
Feb-23-23 07:00AM	Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023 (PR Newswire) -15.24%
Jan-05-23 07:00AM	Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh (PR Newswire)
Jan-04-23 07:00AM	Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes (PR Newswire) +9.43%
Dec-15-22 07:00AM	Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh (PR Newswire)
Dec-14-22 07:00AM	Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer (PR Newswire)
Dec-02-22 08:15AM	Genprex to Present at Upcoming December Investor Conference (PR Newswire)
Oct-24-22 09:45AM	We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate (Simply Wall St.)
Oct-07-22 07:45AM	Genprex to Present at Upcoming October Investor and Industry Conferences (PR Newswire)
Sep-08-22 08:15AM	Genprex to Present at Upcoming September Investor Conference (PR Newswire)
Aug-16-22 07:00AM	Genprex Announces U.S. Patent for REQORSA Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers (PR Newswire) +6.70%
Aug-15-22 07:00AM	Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA in Combination with Tagrisso® in Non-Small Cell Lung Cancer (PR Newswire) +18.08%
Jul-13-22 07:00AM	Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit (PR Newswire)
Jun-02-22 07:00AM	Genprex to Present at Upcoming June Investor Conferences (PR Newswire)
May-19-22 08:15AM	Genprex to Present at Upcoming Investor Conference in May 2022 (PR Newswire)
May-17-22 08:23AM	Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation (Simply Wall St.)
May-09-22 08:15AM	Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference (PR Newswire) -9.80%
May-05-22 08:30AM	Genprex Issues Shareholder Letter and Provides 2022 Corporate Update (PR Newswire)
Apr-18-22 08:15AM	Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022 (PR Newswire) -8.04%
Mar-31-22 07:05AM	Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer (Business Wire)
Mar-23-22 08:00AM	Genprex to Participate in Upcoming Investor Conference in March (Business Wire)
Mar-14-22 04:48AM	How to Profit From Solar Energy (Investopedia) -5.69%
Mar-02-22 08:00AM	Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer (Business Wire)
Feb-15-22 09:00AM	Diamond Equity Research to Host Emerging Growth Invitational Virtual Investor Conference on February 24, 2022 (GlobeNewswire) +7.27%
Feb-09-22 08:15AM	Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes (Business Wire)
Jan-31-22 12:04PM	This Biotech Company Has Cancer and Diabetes Treatments in Development (TheStreet.com) +8.74%
Jan-27-22 11:23AM	Preclinical Data Show Potential for Use of Genprexs ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer (Business Wire)
Jan-24-22 07:09AM	JinkoSolar's Subsidiary Jinko Solar Co., Ltd. to be Listed on Shanghai Stock Exchange on January 26, 2022 (PR Newswire)
Jan-10-22 09:17AM	Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA Systemic Gene Therapy in Non-Small Cell Lung Cancer (Business Wire) +6.31%
08:34AM	Sweihan PV Power Company PJSC -- Moody's assigns Baa1 rating to 881MW Noor Abu Dhabi solar PV project; outlook stable (Moody's)
Jan-06-22 08:05AM	JinkoSolar's Subsidiary Jinko Solar Co., Ltd.'s Updated IPO Prospectus and Indicative IPO Timetable Published by the Shanghai Stock Exchange (PR Newswire)
Jan-05-22 08:00AM	Genprex to Participate in January Investor and Healthcare Conferences to Highlight Companys Gene Therapies in Cancer and Diabetes (Business Wire) -18.64%
Jan-04-22 12:27PM	Genprex's (GNPX) Lead Cancer Drug Gets Second Fast Track Tag (Zacks) -20.29%
08:00AM	Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer (Business Wire)
Jan-03-22 02:24PM	Genprex stock more than doubles on very heavy volume after FTD granted for cancer treatment (MarketWatch) +167.18%
12:25PM	GNPX Stock: 5 Things to Know as Genprex Rockets Higher (InvestorPlace)

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company's lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VACZY CATHERINE M	EVP GC Chief Strategy Officer	Apr 21 '23	Buy	1.07	20,000	21,478	265,000	Apr 24 09:00 AM
Varner John Rodney	Chairman, President and CEO	Apr 21 '23	Buy	1.05	19,000	20,045	20,800	Apr 24 09:03 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GNPX

Genprex Inc

Upgrade your FINVIZ experience